Skip to main content
Premium Trial:

Request an Annual Quote

Predicine, Apollomics Partner on NSCLC Liquid Biopsy Assay

NEW YORK — Predicine said on Friday that it has partnered with drug-discovery and- development company Apollomics on a liquid biopsy test that can help personalize treatment of non-small cell lung cancer (NSCLC).

Predicine is developing a next-generation sequencing-based assay, called PredicineCare, that is designed to detect single nucleotide variants, insertions and deletions, DNA rearrangements, and copy number variations in blood or urine that can be used to guide cancer treatment. The 152-gene test received both CE-IVD marking and breakthrough device designation from the US Food and Drug Administration in August 2022.

Earlier this year, Predicine Founder and CEO Shidong Jia said that the Hayward, California-based company has been striking companion diagnostics development agreements for the test with different drugmakers — including Johnson & Johnson, AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Merck, Boehringer Ingelheim, and BeiGene — to aid its efforts to bring the test to market.

Under the terms of Predicine's deal with Foster City, California-based Apollomics, the companies aim to develop PredicineCare for use in identifying NSCLC patients who may benefit from targeted therapies. Apollomics has a small molecule drug in phase II development for NSCLC with MET genomic aberrations.

Additional terms were not disclosed.